A detailed history of Cerity Partners LLC transactions in Grifols Sa stock. As of the latest transaction made, Cerity Partners LLC holds 20,316 shares of GRFS stock, worth $163,950. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,316
Previous 18,229 11.45%
Holding current value
$163,950
Previous $114,000 57.89%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$6.28 - $9.38 $13,106 - $19,576
2,087 Added 11.45%
20,316 $180,000
Q2 2024

Aug 13, 2024

SELL
$6.27 - $7.7 $42,962 - $52,760
-6,852 Reduced 27.32%
18,229 $114,000
Q1 2024

May 14, 2024

SELL
$5.47 - $11.38 $115,695 - $240,698
-21,151 Reduced 45.75%
25,081 $167,000
Q4 2023

Jan 26, 2024

SELL
$7.71 - $11.56 $21,827 - $32,726
-2,831 Reduced 5.77%
46,232 $534,000
Q3 2023

Nov 13, 2023

SELL
$8.91 - $10.91 $32,922 - $40,312
-3,695 Reduced 7.0%
49,063 $448,000
Q2 2023

Aug 14, 2023

BUY
$7.14 - $9.29 $22,269 - $28,975
3,119 Added 6.28%
52,758 $483,000
Q1 2023

May 11, 2023

BUY
$6.65 - $10.69 $53,000 - $85,199
7,970 Added 19.13%
49,639 $365,000
Q4 2022

Feb 15, 2023

SELL
$5.96 - $8.53 $222,671 - $318,689
-37,361 Reduced 47.27%
41,669 $354,000
Q3 2022

Nov 10, 2022

BUY
$5.95 - $14.3 $117,786 - $283,082
19,796 Added 33.42%
79,030 $487,000
Q2 2022

Aug 10, 2022

BUY
$10.6 - $13.28 $627,880 - $786,627
59,234 New
59,234 $703,000
Q1 2022

Apr 25, 2022

SELL
$10.37 - $12.73 $140,586 - $172,580
-13,557 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$10.21 - $15.27 $138,416 - $207,015
13,557 New
13,557 $153,000

Others Institutions Holding GRFS

About Grifols SA


  • Ticker GRFS
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 678,910,976
  • Market Cap $5.48B
  • Description
  • Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...
More about GRFS
Track This Portfolio

Track Cerity Partners LLC Portfolio

Follow Cerity Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cerity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cerity Partners LLC with notifications on news.